Skip to main content

Market Overview

Recap: Agenus Q1 Earnings

Share:

Shares of Agenus (NASDAQ:AGEN) rose 3.8% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 266.67% over the past year to ($0.20), which beat the estimate of ($0.33).

Revenue of $15,128,000 less by 81.06% year over year, which beat the estimate of $12,350,000.

Looking Ahead

Agenus hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 07, 2020

Webcast URL: https://www.webcaster4.com/Webcast/Page/1556/34323

Recent Stock Performance

Company's 52-week high was at $4.57

Company's 52-week low was at $1.82

Price action over last quarter: Up 7.94%

Company Profile

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

 

Related Articles (AGEN)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com